Prevalence of drugs used for chronic conditions after diagnosis of thyroid cancer: a register-based cohort study
Authors' conclusion
Individuals diagnosed with thyroid cancer had elevated long-term use of drugs for several chronic conditions, as compared with the cancer-free population.
Study context
- Population
- Norwegian population linked from the Cancer Registry of Norway to the Norwegian Prescription Database; thyroid cancer diagnosed 2005–2019thyroid cancer
- Participants
- 3,486 participants
- Exposure
- Thyroid cancer patients vs cancer-free population
- Thyroid cancern = 3,486
- Outcome
- Prevalence ratios (PRs) of reimbursed prescribed drugs for chronic conditions
- Follow-up
- Up to 15 years after diagnosis
Methodological detailspopulation-wide register data, log-binomial regression
- Population-wide register data
- Log-binomial regression
Main finding
As reported in the abstract
Use of drugs for chronic conditions · 5 years after diagnosis
- Thyroid cancer
- PR, males: hypoparathyroidism 35.4 (95% CI 25.2–49.7)
- Thyroid cancer
- PR, females: hypoparathyroidism 42.8 (95% CI 34.2–53.6)
- Thyroid cancer
- PR, females: hypertension 1.20 (95% CI 1.12–1.28)
- Thyroid cancer
- PR, males: anxiety and tension 4.01 (95% CI 1.80–8.92)
- Thyroid cancer
- PR, females: anxiety and tension 2.01 (95% CI 1.15–3.52)
- Thyroid cancer
- PR, males: gastric acid disorders 1.52 (95% CI 1.22–1.91)
- Thyroid cancer
- PR, females: gastric acid disorders 1.45 (95% CI 1.27–1.66)
- Thyroid cancer
- PR, males: pain 1.48 (95% CI 1.11–1.97)
- Thyroid cancer
- PR, females: pain 1.24 (95% CI 1.08–1.42)
Observational data: associations, not effects.
Further findings
| Outcome | PR, males (95% CI) |
|---|---|
| Drugs for depression, males · year 10+ | 1.66 (1.06–2.59) |
Drug use before diagnosis · prior to diagnosis
- Higher use of drugs for several conditions prior to diagnosis, eg, hypertension, gastric acid disorders and pain
Original publication
Prevalence of drugs used for chronic conditions after diagnosis of thyroid cancer: a register-based cohort study. Eur J Endocrinol. Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →